EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On May 15, 2018, the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors. The Board appointed Steven J. Boyd as a Class I director of the Company to fill the vacancy created by the increase in the size of the Board, effective as of May 15, 2018, to serve in office until the 2019 annual meeting of stockholders or until his successor is duly elected and qualified or until his earlier resignation or removal.
Mr. Boyd is the Chief Investment Officer of Armistice Capital (“Armistice”), a long-short equity hedge fund focused on the health care and consumer sectors based in New York City. Previously, Mr. Boyd had been a Research Analyst at Senator Investment Group, York Capital, and SAB Capital Management, where he focused on health care. Mr. Boyd began his career as an Analyst at McKinsey& Company. Mr. Boyd has served as a member of the board of directors of Cerecor Inc., an integrated biopharmaceutical company focused on pediatric healthcare, since April 2017. Mr. Boyd received a B.S. in Economics as well as a B.A. in Political Science from The Wharton School of the University of Pennsylvania.
Mr. Boyd will not receive compensation for his services as a member of the Board. There are no understandings or arrangements between Mr. Boyd and any other person to which he was selected as a director. Mr. Boyd does not have any family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or officer.
As previously disclosed, on April 17, 2018, the Company completed its public offering of 14,730,000 shares of the Company’s common stock, 6.536.4 shares of the Company’s Series C Convertible Preferred Stock (convertible into 20,426,250 shares of common stock) and warrants to purchase 35,156,250 shares of common stock, for aggregate gross proceeds of $11.25 million (the “April 2018 Offering”). An affiliate of Armistice participated in the April 2018 Offering and purchased from the Company (i) 3,150,000 shares of common stock, (ii) 4,092 shares of Series C Convertible Preferred Stock (convertible into 12,787,500 shares of common stock), and (iii) warrants to purchase 15,937,500 shares of common stock, for a total purchase price of $5.1 million.
Also as previously disclosed, on June 14, 2017, the Company completed a public offering of 5,336,667 shares of the Company’s common stock, 1,995 shares of the Company’s Series B Convertible Preferred Stock (convertible into 1,330,000 shares of common stock) and warrants to purchase 6,666,667 shares of common stock, for aggregate gross proceeds of $10.0 million (the “June 2017 Offering” and, together with the April 2018 Offering, the “Offerings”). An affiliate of Armistice participated in the June 2017 Offering and purchased from the Company (i) 1,600,000 shares of common stock, (ii) 600 shares of Series B Convertible Preferred Stock (subsequently converted into 400,000 shares of common stock), and (iii) warrants to purchase 2,000,000 shares of common stock, for a total purchase price of $3.0 million.
Other than the Offerings, there are no transactions in which Mr. Boyd has an interest requiring disclosure to Item 404(a) of Regulation S-K.
On May 16, 2018, the Company issued a press release regarding Mr. Boyd’s appointment.A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.
|Item 9.01.||Financial Statements and Exhibits.|
EYEGATE PHARMACEUTICALS INC ExhibitEX-99.1 2 tv494332_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 EyeGate Pharmaceuticals Announces New Board Member,…To view the full exhibit click
About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.